-
Je něco špatně v tomto záznamu ?
Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis
K. Klíčová, J. Mareš, K. Menšíková, M. Kaiserová, D. Friedecký, P. Kaňovský, M. Strnad, R. Matěj
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
CZ.02.1.01 / 0.0 / 0.0 / 16_019 / 0000868
European Regional Development Fund - ENOCH project
NV19-04-00090
Grant Agency of the Ministry of Health
NLK
BioMedCentral
od 2009-12-01
BioMedCentral Open Access
od 2009
Directory of Open Access Journals
od 2012
Free Medical Journals
od 2012
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2012-01-01
Medline Complete (EBSCOhost)
od 2015-06-01
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1995
Springer Nature OA/Free Journals
od 2009-12-01
- MeSH
- amyotrofická laterální skleróza * diagnóza MeSH
- biologické markery MeSH
- klusterin MeSH
- lidé MeSH
- opožděná diagnóza MeSH
- proteiny tau MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive deterioration of upper and lower motor neurons. A definitive diagnostic test or biomarker for ALS is currently unavailable, leading to a diagnostic delay following the onset of initial symptoms. Our study focused on cerebrospinal fluid (CSF) concentrations of clusterin, tau protein, phosphorylated tau protein, and beta-amyloid1-42 in ALS patients and a control group. METHODS: Our study involved 54 ALS patients and 58 control subjects. Among the ALS patients, 14 presented with bulbar-onset ALS, and 40 with limb-onset ALS. We quantified biomarker levels using enzyme-linked immunosorbent assay (ELISA) and compared the results using the Mann-Whitney U-test. RESULTS: Significant elevations in neurodegenerative markers, including tau protein (p < 0.0001), phosphorylated tau protein (p < 0.0001), and clusterin (p = 0.038), were observed in ALS patients compared to controls. Elevated levels of tau protein and phosphorylated tau protein were also noted in both bulbar and limb-onset ALS patients. However, no significant difference was observed for beta-amyloid1-42. ROC analysis identified tau protein (AUC = 0.767) and p-tau protein (AUC = 0.719) as statistically significant predictors for ALS. CONCLUSION: Our study demonstrates that neurodegenerative marker levels indicate an ongoing neurodegenerative process in ALS. Nonetheless, the progression of ALS cannot be predicted solely based on these markers. The discovery of a specific biomarker could potentially complement existing diagnostic criteria for ALS.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007639
- 003
- CZ-PrNML
- 005
- 20240423160142.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s40001-023-01596-4 $2 doi
- 035 __
- $a (PubMed)38184629
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Klíčová, Kateřina $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic. katerina.klicova@fnol.cz
- 245 10
- $a Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis / $c K. Klíčová, J. Mareš, K. Menšíková, M. Kaiserová, D. Friedecký, P. Kaňovský, M. Strnad, R. Matěj
- 520 9_
- $a BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive deterioration of upper and lower motor neurons. A definitive diagnostic test or biomarker for ALS is currently unavailable, leading to a diagnostic delay following the onset of initial symptoms. Our study focused on cerebrospinal fluid (CSF) concentrations of clusterin, tau protein, phosphorylated tau protein, and beta-amyloid1-42 in ALS patients and a control group. METHODS: Our study involved 54 ALS patients and 58 control subjects. Among the ALS patients, 14 presented with bulbar-onset ALS, and 40 with limb-onset ALS. We quantified biomarker levels using enzyme-linked immunosorbent assay (ELISA) and compared the results using the Mann-Whitney U-test. RESULTS: Significant elevations in neurodegenerative markers, including tau protein (p < 0.0001), phosphorylated tau protein (p < 0.0001), and clusterin (p = 0.038), were observed in ALS patients compared to controls. Elevated levels of tau protein and phosphorylated tau protein were also noted in both bulbar and limb-onset ALS patients. However, no significant difference was observed for beta-amyloid1-42. ROC analysis identified tau protein (AUC = 0.767) and p-tau protein (AUC = 0.719) as statistically significant predictors for ALS. CONCLUSION: Our study demonstrates that neurodegenerative marker levels indicate an ongoing neurodegenerative process in ALS. Nonetheless, the progression of ALS cannot be predicted solely based on these markers. The discovery of a specific biomarker could potentially complement existing diagnostic criteria for ALS.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a amyotrofická laterální skleróza $x diagnóza $7 D000690
- 650 _2
- $a klusterin $7 D051152
- 650 _2
- $a opožděná diagnóza $7 D057210
- 650 _2
- $a proteiny tau $7 D016875
- 650 _2
- $a biologické markery $7 D015415
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mareš, Jan $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Menšíková, Kateřina $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Kaiserová, Michaela $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Friedecký, David $u Laboratory of Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic Olomouc, Czech Republic
- 700 1_
- $a Kaňovský, Petr $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Strnad, Miroslav $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic $u Laboratory of Growth Regulators, Faculty of Science and Institute of Experimental Botany of the Czech Academy of Sciences, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Matěj, Radoslav $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00181709 $t European journal of medical research $x 2047-783X $g Roč. 29, č. 1 (2024), s. 31
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38184629 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423160138 $b ABA008
- 999 __
- $a ok $b bmc $g 2081558 $s 1217406
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 29 $c 1 $d 31 $e 20240106 $i 2047-783X $m European journal of medical research $n Eur J Med Res $x MED00181709
- GRA __
- $a CZ.02.1.01 / 0.0 / 0.0 / 16_019 / 0000868 $p European Regional Development Fund - ENOCH project
- GRA __
- $a NV19-04-00090 $p Grant Agency of the Ministry of Health
- LZP __
- $a Pubmed-20240412